Wisconsin Alumni Research Foundation

Pharmaceuticals & Vitamin D
Pharmaceuticals Vitamin D
Synstatin “SSTNEGFR” Fights Cancer
WARF: P120300US03

Inventors: Alan Rapraeger

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a peptide that can inhibit and kill tumors by blocking a key receptor interaction.
Overview
EGFR (epidermal growth factor receptor) exists on the cell surface and is a member of a family of closely related receptor tyrosine kinases. Overexpression of EGFR can result in cancer. In particular, EGFR plays a major role in lung cancer, triple negative breast cancer and head and neck carcinoma.

It is known that EGFR couples with another type of receptor, α6β4 integrin, found on cell surfaces. The two receptors form a signaling complex that drives tumor growth, invasion and survival. How they interact and start this process has remained mysterious until now. The answer may lead to groundbreaking new cancer treatments.
The Invention
A UW–Madison researcher has discovered that the EGFR/α6β4 assembly is mediated by the syndecan family of matrix receptors. Specifically, syndecan-4 (Sdc4) links the two receptors together and helps tumor cells grow and survive.

To obstruct this process, the researcher has created a recombinant peptide that competes with Sdc4 for binding partners. The new peptide is derived from Sdc4 but is harmless. It is called SSTNEGFR. It can be administered as a drug and combined with cancer patients’ other therapies.
Applications
  • Treating carcinoma, myeloma, melanoma, schwannoma, malignant endothelial cells or glioma
  • May help scarring and other pathological wound healing
Key Benefits
  • Targets growth, survival and invasion of tumor cells
  • May target tumor angiogenesis
  • Does not hurt normal cells
Additional Information
For More Information About the Inventors
Publications
  • Rapraeger A.C. 2013. Synstatin: a Selective Inhibitor of the Syndecan-1-coupled IGF1R-αvβ3 Integrin Complex in Tumorigenesis and Angiogenesis. FEBS J. 280, 2207-2215.
  • Wang H., Leavitt L., Ramaswamy R. and Rapraeger A.C. 2010. Interaction of Syndecan and alpha6beta4 Integrin Cytoplasmic Domains: Regulation of ErbB2-Mediated Integrin Activation. J. Biol. Chem. 285, 13569-13579.
For current licensing status, please contact Andy DeTienne at [javascript protected email address] or 608-960-9857

WARF